Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment (U.S. Patent Application Number 20070099836)

Acronym: Not Available NIDDK Contact: Principal Investigator(s): Phillip Gorden


Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods. Methods of the present invention contemplate administration of leptin, leptin analogs, and leptin derivatives to patients having a leptin level of approximately 4 ng/ml or less before treatment.

Click outside of the light box to close the box.